The Experts below are selected from a list of 10743 Experts worldwide ranked by ideXlab platform
Neal L. Benowitz - One of the best experts on this subject based on the ideXlab platform.
-
Impact of CYP2A6 genotype on pretreatment smoking behaviour and Nicotine levels from and usage of Nicotine Replacement Therapy
Molecular Psychiatry, 2006Co-Authors: Viba Malaiyandi, C Lerman, F Patterson, Catherine Jepson, Neal L. Benowitz, Rachel F TyndaleAbstract:We investigated the effect of slow metabolism of Nicotine, predicted by CYP2A6 genotypes resulting in ⩽50% activity, on baseline smoking behaviours and treatment variables in an open-label Nicotine Replacement Therapy (NRT) clinical trial. Caucasian smokers with CYP2A6 slow vs normal metabolism had lower metabolic activity, indicated by the 3-hydroxycotinine/cotinine ratio (0.23±0.17 vs 0.45±0.22, P
-
Impact of CYP2A6 genotype on pretreatment smoking behaviour and Nicotine levels from and usage of Nicotine Replacement Therapy.
Molecular psychiatry, 2006Co-Authors: Viba Malaiyandi, C Lerman, F Patterson, Neal L. Benowitz, Christopher Jepson, Rachel F TyndaleAbstract:Impact of CYP2A6 genotype on pretreatment smoking behaviour and Nicotine levels from and usage of Nicotine Replacement Therapy
-
Anabasine and anatabine as biomarkers for tobacco use during Nicotine Replacement Therapy.
Cancer epidemiology biomarkers & prevention : a publication of the American Association for Cancer Research cosponsored by the American Society of Pre, 2002Co-Authors: Peyton Jacob, Dorothy K. Hatsukami, Herbert Severson, Sharon M. Hall, Neal L. BenowitzAbstract:In this study we determined urine concentration of the tobacco alkaloids anabasine and anatabine, Nicotine and its metabolites cotinine, and norNicotine in 99 cigarette smokers and 205 smokeless tobacco users. We also investigated the possibility that anabasine and anatabine can be used as biomarkers for tobacco use during Nicotine Replacement Therapy. Urine samples and data on self-reported tobacco use were obtained from subjects enrolled in tobacco cessation programs. Urine concentrations of tobacco alkaloids and metabolites were measured and correlated with self-reported tobacco use. Concentrations of anabasine and anatabine were used to validate abstinence in smokeless tobacco users who used Nicotine gum as part of the Therapy. Correlations of alkaloid concentration with self-reported tobacco use before treatment ranged from fair to poor. In subjects abstaining from smokeless tobacco but using Nicotine gum, anabasine and anatabine levels were below the cut-point of 2 ng/ml despite high concentrations of Nicotine and cotinine resulting from Nicotine gum use. Anabasine and anatabine concentrations in urine can be used to validate abstinence or measure the extent of tobacco use in persons undergoing Nicotine Replacement Therapy.
-
The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients
Drugs & Aging, 1996Co-Authors: Steven G. Gourlay, Neal L. BenowitzAbstract:Considerable benefits accrue from stopping smoking in older patients. Reversal of the short term cardiovascular adverse effects of smoking is rapid. Long term risk reduction appears to occur as a resuit of decreased life-time exposure to tobaceo smoke. The pharmacology of Nicotine has not been studied in older patients but is unlikely to change in clinically important ways with advancing age. Nicotine Replacement doubles long term success rates, compared with placebo, among younger smokers of ≥10 cigarettes per day. There is no reason to believe its efficacy should be less among older smokers. Transdermal Nicotine is the Replacement Therapy of choice in older patients because of once-daily administration and good tolerability. Approximately half of the users of transdermal Nicotine smoke concurrently with treatment. It is unlikely that concurrent smoking or high doses of Nicotine Replacement Therapy will adversely effect healthy patients. While it is generally believed that patients with unstable coronary heart disease may be at risk from concurrent smoking during Nicotine Replacement Therapy, it is unclear whether this risk is greater than the risk of smoking alone. Nicotine Replacement Therapy is a logical approach for motivated, older smokers who are unable to stop smoking by simpler means. Results can be augmented by including other interventions, such as counselling and follow-up support.
-
The benefits of stopping smoking and the role of Nicotine Replacement Therapy in older patients.
Drugs & aging, 1996Co-Authors: Steven G. Gourlay, Neal L. BenowitzAbstract:Considerable benefits accrue from stopping smoking in older patients. Reversal of the short term cardiovascular adverse effects of smoking is rapid. Long term risk reduction appears to occur as a result of decreased life-time exposure to tobacco smoke. The pharmacology of Nicotine has not been studied in older patients but is unlikely to change in clinically important ways with advancing age. Nicotine Replacement doubles long term success rates, compared with placebo, among younger smokers of > or = cigarettes per day. There is no reason to believe its efficacy should be less among older smokers. Transdermal Nicotine is the Replacement Therapy of choice in older patients because of once-daily administration and good tolerability. Approximately half of the users of transdermal Nicotine smoke concurrently with treatment. It is unlikely that concurrent smoking or high doses of Nicotine Replacement Therapy will adversely effect healthy patients. While it is generally believed that patients with unstable coronary heart disease may be at risk from concurrent smoking during Nicotine Replacement Therapy, it is unclear whether this risk is greater than the risk of smoking alone. Nicotine Replacement Therapy is a logical approach for motivated, older smokers who are unable to stop smoking by simpler means. Results can be augmented by including other interventions, such as counselling and follow-up support.
Rachel F Tyndale - One of the best experts on this subject based on the ideXlab platform.
-
Developmental hippocampal neuroplasticity in a model of Nicotine Replacement Therapy during pregnancy and breastfeeding.
PloS one, 2012Co-Authors: Ian Mahar, Rachel F Tyndale, Rosemary C. Bagot, Maria Antonietta Davoli, Sharon Miksys, Claire-dominique Walker, Marissa Maheu, Sheng-hai Huang, Tak Pan Wong, Naguib MechawarAbstract:Rationale The influence of developmental Nicotine exposure on the brain represents an important health topic in light of the popularity of Nicotine Replacement Therapy (NRT) as a smoking cessation method during pregnancy.
-
Impact of CYP2A6 genotype on pretreatment smoking behaviour and Nicotine levels from and usage of Nicotine Replacement Therapy
Molecular Psychiatry, 2006Co-Authors: Viba Malaiyandi, C Lerman, F Patterson, Catherine Jepson, Neal L. Benowitz, Rachel F TyndaleAbstract:We investigated the effect of slow metabolism of Nicotine, predicted by CYP2A6 genotypes resulting in ⩽50% activity, on baseline smoking behaviours and treatment variables in an open-label Nicotine Replacement Therapy (NRT) clinical trial. Caucasian smokers with CYP2A6 slow vs normal metabolism had lower metabolic activity, indicated by the 3-hydroxycotinine/cotinine ratio (0.23±0.17 vs 0.45±0.22, P
-
Impact of CYP2A6 genotype on pretreatment smoking behaviour and Nicotine levels from and usage of Nicotine Replacement Therapy.
Molecular psychiatry, 2006Co-Authors: Viba Malaiyandi, C Lerman, F Patterson, Neal L. Benowitz, Christopher Jepson, Rachel F TyndaleAbstract:Impact of CYP2A6 genotype on pretreatment smoking behaviour and Nicotine levels from and usage of Nicotine Replacement Therapy
Daniel Kotz - One of the best experts on this subject based on the ideXlab platform.
-
effectiveness of varenicline versus Nicotine Replacement Therapy for smoking cessation with minimal professional support evidence from an english population study
Psychopharmacology, 2014Co-Authors: Jamie Brown, Daniel Kotz, Robert WestAbstract:Rationale Limited evidence from randomised controlled trials suggests that varenicline might be more effective than Nicotine Replacement Therapy (NRT) in achieving abstinence from smoking. The comparative effectiveness of varenicline when prescribed under routine circumstances and in the general population has not been tested.
Gary E. Swan - One of the best experts on this subject based on the ideXlab platform.
-
Tailoring Nicotine Replacement Therapy
CNS Drugs, 2006Co-Authors: Jennifer B. Mcclure, Gary E. SwanAbstract:Nicotine Replacement Therapy (NRT) is an effective treatment for smoking cessation, but as with all such pharmacotherapies, the majority of smokers who use NRT products do not stop smoking or remain abstinent long term. Treatment outcome is affected by a range of individual-specific factors, as well as the pharmacokinetic profile of each NRT formulation. This has led to speculation that abstinence rates could be improved if NRT treatments were individually tailored to best match each individual’s needs and preferences. There are also populations for whom special product and dosage considerations are warranted to maximise treatment safety. This paper reviews the rationale for NRT treatment, standard dose recommendations and recommendations for how to best match NRT treatment to the specific needs of individual smokers. We also review emerging evidence that genetic profiling may one day be a useful consideration for tailoring NRT treatment.
-
Tailoring Nicotine Replacement Therapy: rationale and potential approaches.
CNS drugs, 2006Co-Authors: Jennifer B. Mcclure, Gary E. SwanAbstract:Nicotine Replacement Therapy (NRT) is an effective treatment for smoking cessation, but as with all such pharmacotherapies, the majority of smokers who use NRT products do not stop smoking or remain abstinent long term. Treatment outcome is affected by a range of individual-specific factors, as well as the pharmacokinetic profile of each NRT formulation. This has led to speculation that abstinence rates could be improved if NRT treatments were individually tailored to best match each individual’s needs and preferences. There are also populations for whom special product and dosage considerations are warranted to maximise treatment safety.
Shane M. Tibby - One of the best experts on this subject based on the ideXlab platform.
-
Safety of Nicotine Replacement Therapy in critically ill smokers: a retrospective cohort study
Intensive care medicine, 2012Co-Authors: Michael A. Gillies, Catherine Mckenzie, Craig Whiteley, Richard Beale, Shane M. TibbyAbstract:Purpose Nicotine Replacement Therapy (NRT) has been used to ameliorate Nicotine withdrawal in the intensive care unit (ICU). Previous cohort studies have suggested an increased mortality with NRT use: methodological problems may call into question the validity of these findings. We undertook a retrospective cohort study to determine if NRT use was associated with adverse outcomes.
